Novavax jumps as FDA clears COVID-19 vaccine

peterschreiber.media

Novavax (NASDAQ:NVAX) shares climbed more than 17% premarket on Monday after the long-awaited approval of its COVID-19 vaccine from the U.S. FDA.

The FDA cleared the biologics license application for Nuvaxovid for immunization against COVID-19 in adults 65 years and older